These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 17915581

  • 1. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
    Karel I.
    Cesk Slov Oftalmol; 2007 Sep; 63(5):311-9. PubMed ID: 17915581
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I.
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [Abstract] [Full Text] [Related]

  • 4. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H, Gierek-Lapińska A, Trzciakowski K, Gajdzik-Gajdecka U.
    Klin Oczna; 2007 Dec; 109(10-12):402-9. PubMed ID: 18488382
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography.
    You JY, Chung H, Kim HC.
    Curr Eye Res; 2012 May; 37(5):438-45. PubMed ID: 22510011
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 May; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 7. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV, Steén B, Seregard S, Kvanta A.
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [Abstract] [Full Text] [Related]

  • 8. [Combined therapy in the exsudative age-related macular degeneration (photodynamic therapy and intravitreally-applied ranibizumab)].
    Ernest J, Hejsek L, Benesová Z, Ová Z, Remont L, Nemec P.
    Cesk Slov Oftalmol; 2010 Jul; 66(3):119-23, 126. PubMed ID: 21137472
    [Abstract] [Full Text] [Related]

  • 9. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
    Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.
    Health Technol Assess; 2008 May; 12(16):iii-iv, ix-201. PubMed ID: 18462575
    [Abstract] [Full Text] [Related]

  • 10. Photodynamic therapy for polypoidal choroidal vasculopathy.
    Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AH.
    Prog Retin Eye Res; 2013 Nov; 37():182-99. PubMed ID: 24140257
    [Abstract] [Full Text] [Related]

  • 11. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, Azarmina M, Dehghan MH, Moradian S.
    BMC Ophthalmol; 2007 Jun 07; 7():10. PubMed ID: 17555600
    [Abstract] [Full Text] [Related]

  • 12. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM.
    Retina; 2006 Jun 07; 26(9):994-8. PubMed ID: 17151485
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Photodynamic therapy with intravitreal application of triamcinolone acetonide in age-related macular degeneration: functional results in 54 patients.
    Frimpong-Boateng A, Bunse A, Rüfer F, Roider J.
    Acta Ophthalmol; 2009 Mar 07; 87(2):183-7. PubMed ID: 18547278
    [Abstract] [Full Text] [Related]

  • 15. [Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV)].
    Maier M, Feucht N, Haas K, Fiore B, Winkler von Mohrenfels C, Clos A, Lohmann C.
    Klin Monbl Augenheilkd; 2008 Sep 07; 225(9):818-24. PubMed ID: 18759214
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke.
    Cleary CA, Sharaznayan D, Hickey-Dwyer M.
    Ir Med J; 2011 May 07; 104(5):146-9. PubMed ID: 21736091
    [Abstract] [Full Text] [Related]

  • 18. [Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study].
    Baeteman C, Hoffart L, Galland F, Ridings B, Conrath J.
    J Fr Ophtalmol; 2009 May 07; 32(5):309-13. PubMed ID: 19769866
    [Abstract] [Full Text] [Related]

  • 19. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.
    Klin Monbl Augenheilkd; 2007 Sep 07; 224(9):727-32. PubMed ID: 17846963
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR, Moride Y, Rochon S.
    Clin Ther; 2007 Sep 07; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.